Treatment of multidrug-resistant Gram-negative infections in children.
about
Beyond Susceptible and Resistant, Part III: Treatment of Infections due to Gram-Negative Organisms Producing CarbapenemasesUse of Carbapenems, Polymyxins, and Tigecycline in United States Children's Hospitals, 2010-2014Clinical and laboratory considerations for the rapid detection of carbapenem-resistant Enterobacteriaceae.Extended-spectrum β-lactamase-producing Enterobacteriaceae in children: old foe, emerging threat.Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremiaPharmacokinetics and pharmacodynamics of continuous-infusion meropenem in pediatric hematopoietic stem cell transplant patientsCarbapenem-Resistant Enterobacteriaceae in Children, United States, 1999-2012.Suspicion of respiratory tract infection with multidrug-resistant Enterobacteriaceae: epidemiology and risk factors from a Paediatric Intensive Care UnitComplete genome sequence of Acinetobacter baumannii XH386 (ST208), a multi-drug resistant bacteria isolated from pediatric hospital in China.Analysis of β-Lactamase Resistance Determinants in Enterobacteriaceae from Chicago Children: a Multicenter SurveyCarbapenem-Resistant Enterobacteriaceae Infections in Children.Treatment option for sepsis in children in the era of antibiotic resistance.Use of Tigecycline in Pediatric Patients With Infections Predominantly Due to Extensively Drug-Resistant Gram-Negative Bacteria.Clinical Characteristics of Bloodstream Infections in Pediatric Acute Leukemia: A Single-center Experience with 231 Patients.Population Pharmacokinetics of High Dose Continuous Infusion Meropenem and Considerations for the Use in the Treatment of Infections due to KPC-Producing Klebsiella pneumoniae.Determining the optimal ceftriaxone MIC for triggering extended-spectrum β-lactamase confirmatory testing.Use of Antibiotics Reserved for Resistant Gram-Negative Infections at Freestanding U.S. Children's Hospitals from 2004 to 2014.Evaluation of automated systems for aminoglycosides and fluoroquinolones susceptibility testing for Carbapenem-resistant Enterobacteriaceae.Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial inMonitoring and managing antibiotic resistance in refugee children.Once-daily intramuscular amikacin for outpatient treatment of lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli in children.Occurrence of antimicrobial agents, drug-resistant bacteria, and genes in the sewage-impacted Vistula River (Poland).Facilitators and barriers to the successful implementation of pediatric antibacterial drug trials: Findings from CTTI's survey of investigators.Antibiotic combination efficacy (ACE) networks for a Pseudomonas aeruginosa model.Acquisition of extended spectrum beta-lactamase-producing enterobacteriaceae in neonates: A community based cohort in Madagascar.First report of neonatal bacteraemia caused by blaNDM-1 Raoultella ornithinolytica
P2860
Q26747580-CA097C5B-7CF6-442F-9F96-0DD1A2B50D7CQ33609472-E6D932B2-C164-4381-BA10-E40FD13586C0Q33816207-186F45B7-894E-4C33-9671-E6DAE0AC2997Q35555196-A9FF86E3-C04F-4099-938F-A868D03355ADQ35715650-0D447D53-07DA-4D25-94D5-CCD0DF263546Q35960828-B5E2EF5D-548F-4B44-A131-6F1E5CA05C7AQ36212092-21F4FC24-9648-4E91-A4ED-B335AAA023C4Q36286719-C07CA726-7919-4361-8578-2D492EF3E778Q36652660-DCDB5CC4-BE97-4D53-AB51-41545CF90982Q36933460-EA007D7B-A802-4047-87D1-ADF269F226A0Q37154718-DFDD0AFD-2544-4713-B82A-D422ACD118AAQ38246118-322FB3CF-0FE5-454C-97C1-B48CC17A2678Q38783940-E8F1626A-50FB-4524-A345-BA010740F13BQ40042111-BCE3DBF3-BE89-411A-A59B-3B1092CBD32EQ40112541-8FF0BB46-0C3D-415A-B4F1-3E71C853AF7CQ40212000-901417F5-745E-48B2-884D-B4BE24300853Q40690061-B4148547-7EA8-4E73-B055-4F2B68E1A6F8Q41215201-54AEF372-CADA-47E1-ACF9-E0BCBFF58FEAQ41349399-7E2601AC-DFCD-4D00-9C8D-232DDC6C49BEQ46658147-522DCE89-644F-430B-B68E-867B521B8BBDQ47595207-2B5763F4-8E1F-4DDC-B6C0-44FC037B556AQ47757940-706A1B69-CBB4-4BFD-9646-AF35B924BD14Q52562486-4F1E9BF3-B5F6-4B6C-A9D7-4357B1D67B58Q53690104-91AF32D7-3166-4CB3-B5D4-58250330ED3BQ53701512-0C7E83AD-DF50-447E-90B9-211B144DA0C3Q57990067-7D464B20-D45A-44BE-BF9C-1B4AFA20B37B
P2860
Treatment of multidrug-resistant Gram-negative infections in children.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Treatment of multidrug-resistant Gram-negative infections in children.
@en
type
label
Treatment of multidrug-resistant Gram-negative infections in children.
@en
prefLabel
Treatment of multidrug-resistant Gram-negative infections in children.
@en
P2860
P356
P1476
Treatment of multidrug-resistant Gram-negative infections in children.
@en
P2093
Alice J Hsu
Pranita D Tamma
P2860
P304
P356
10.1093/CID/CIU069
P407
P577
2014-02-05T00:00:00Z